Pharmaceutical

EMA endorses AbbVie’s Skyrizi for ulcerative colitis

The EMA’s CHMP gave a positive opinion for Abbvie’s Skyrizi as the company bolsters its immunology pipeline.

Jun 2, 2024 - 04:00
EMA endorses AbbVie’s Skyrizi for ulcerative colitis
The EMA’s CHMP gave a positive opinion for Abbvie’s Skyrizi as the company bolsters its immunology pipeline.
Read the original article

Tags:

Previous Article

Dupixent gets closer to EU approval as the FDA delays its decision on COPD

Next Article

Manufacturing inspections down in China amid arrest fears and no access

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: I’m a biopharma supply chain specialist — and even I can’t find the Adderall I’m prescribed

Opinion: I’m a biopharma supply chain specialist — and ...

Apr 15, 2023

Forge Biologics joins BGTC for new AAV gene therapies development

Forge Biologics joins BGTC for new AAV gene therapies d...

May 24, 2023

Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?

Why did Allogene cancel two clinical trials for its off...

Jan 6, 2024